iSpecimen Inc. Logo

iSpecimen Inc.

ISPC

(1.8)
Stock Price

3,90 USD

-189% ROA

-115.37% ROE

-5.23x PER

Market Cap.

3.080.620,00 USD

0.48% DER

0% Yield

-97.04% NPM

iSpecimen Inc. Stock Analysis

iSpecimen Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

iSpecimen Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.4x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (2%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

4 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

5 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

6 ROE

The stock's ROE indicates a negative return (-59%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-59.57%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

iSpecimen Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

iSpecimen Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

iSpecimen Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

iSpecimen Inc. Revenue
Year Revenue Growth
2018 4.394.818
2019 4.298.350 -2.24%
2020 8.184.106 47.48%
2021 11.135.303 26.5%
2022 10.402.303 -7.05%
2023 11.111.004 6.38%
2023 9.928.184 -11.91%
2024 11.454.716 13.33%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

iSpecimen Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2018 1.210.079
2019 993.329 -21.82%
2020 1.426.473 30.36%
2021 1.837.882 22.38%
2022 2.656.287 30.81%
2023 3.686.320 27.94%
2023 4.597.320 19.82%
2024 4.197.752 -9.52%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

iSpecimen Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 2.191.225
2019 2.851.373 23.15%
2020 3.307.222 13.78%
2021 6.976.998 52.6%
2022 8.928.664 21.86%
2023 4.409.492 -102.49%
2023 7.723.971 42.91%
2024 5.954.260 -29.72%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

iSpecimen Inc. EBITDA
Year EBITDA Growth
2018 -2.843.896
2019 -3.075.635 7.53%
2020 -1.576.602 -95.08%
2021 -5.958.380 73.54%
2022 -10.006.959 40.46%
2023 -8.426.544 -18.76%
2023 -9.103.720 7.44%
2024 -6.299.720 -44.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

iSpecimen Inc. Gross Profit
Year Gross Profit Growth
2018 2.032.323
2019 2.170.450 6.36%
2020 4.598.629 52.8%
2021 5.886.290 21.88%
2022 5.645.338 -4.27%
2023 5.540.868 -1.89%
2023 3.042.288 -82.13%
2024 3.330.172 8.64%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

iSpecimen Inc. Net Profit
Year Net Profit Growth
2018 -5.347.052
2019 -4.727.050 -13.12%
2020 -6.758.533 30.06%
2021 -10.015.968 32.52%
2022 -9.040.723 -10.79%
2023 -8.444.404 -7.06%
2023 -11.099.488 23.92%
2024 -8.436.096 -31.57%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

iSpecimen Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -1
2019 -1 0%
2020 -1 100%
2021 -1 0%
2022 -1 0%
2023 -1 0%
2023 -1 100%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

iSpecimen Inc. Free Cashflow
Year Free Cashflow Growth
2018 -3.707.386
2019 -4.155.145 10.78%
2020 -1.390.992 -198.72%
2021 -11.706.327 88.12%
2022 -9.008.910 -29.94%
2023 -1.480.673 -508.43%
2023 -10.552.135 85.97%
2024 -1.711.452 -516.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

iSpecimen Inc. Operating Cashflow
Year Operating Cashflow Growth
2018 -2.681.749
2019 -2.679.900 -0.07%
2020 -288.380 -829.29%
2021 -10.668.410 97.3%
2022 -5.817.720 -83.38%
2023 -1.480.673 -292.91%
2023 -5.807.550 74.5%
2024 -1.539.251 -277.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

iSpecimen Inc. Capital Expenditure
Year Capital Expenditure Growth
2018 1.025.637
2019 1.475.245 30.48%
2020 1.102.612 -33.8%
2021 1.037.917 -6.23%
2022 3.191.190 67.48%
2023 0 0%
2023 4.744.585 100%
2024 172.201 -2655.26%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

iSpecimen Inc. Equity
Year Equity Growth
2018 -18.423.752
2019 -22.718.749 18.91%
2020 -27.277.967 16.71%
2021 29.791.588 191.56%
2022 20.309.170 -46.69%
2023 12.705.720 -59.84%
2023 9.741.077 -30.43%
2024 6.089.284 -59.97%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

iSpecimen Inc. Assets
Year Assets Growth
2018 4.044.626
2019 4.214.588 4.03%
2020 6.209.696 32.13%
2021 35.719.598 82.62%
2022 24.617.653 -45.1%
2023 16.295.096 -51.07%
2023 15.819.137 -3.01%
2024 11.901.858 -32.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

iSpecimen Inc. Liabilities
Year Liabilities Growth
2018 22.468.378
2019 26.933.337 16.58%
2020 33.487.663 19.57%
2021 5.928.010 -464.91%
2022 4.308.483 -37.59%
2023 3.589.376 -20.03%
2023 6.078.060 40.95%
2024 5.812.574 -4.57%

iSpecimen Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.93
Net Income per Share
-0.9
Price to Earning Ratio
-5.23x
Price To Sales Ratio
0.29x
POCF Ratio
-10.89
PFCF Ratio
-0.42
Price to Book Ratio
8.76
EV to Sales
0.09
EV Over EBITDA
-0.11
EV to Operating CashFlow
-0.2
EV to FreeCashFlow
-0.13
Earnings Yield
-0.19
FreeCashFlow Yield
-2.39
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
3.3
Graham NetNet
-0.13

Income Statement Metrics

Net Income per Share
-0.9
Income Quality
0.48
ROE
-1.15
Return On Assets
-0.86
Return On Capital Employed
-1.68
Net Income per EBT
1
EBT Per Ebit
0.99
Ebit per Revenue
-0.98
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.75
Research & Developement to Revenue
0.41
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.34
Operating Profit Margin
-0.98
Pretax Profit Margin
-0.97
Net Profit Margin
-0.97

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.43
Free CashFlow per Share
-0.65
Capex to Operating CashFlow
-0.5
Capex to Revenue
0.23
Capex to Depreciation
1.08
Return on Invested Capital
-1.7
Return on Tangible Assets
-1.89
Days Sales Outstanding
98.89
Days Payables Outstanding
219.75
Days of Inventory on Hand
0
Receivables Turnover
3.69
Payables Turnover
1.66
Inventory Turnover
0
Capex per Share
0.22

Balance Sheet

Cash per Share
0,19
Book Value per Share
0,54
Tangible Book Value per Share
-0.04
Shareholders Equity per Share
0.54
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.25
Current Ratio
0.9
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
6061683
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.55
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

iSpecimen Inc. Dividends
Year Dividends Growth

iSpecimen Inc. Profile

About iSpecimen Inc.

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

CEO
Ms. Tracy Wilson Curley
Employee
53
Address
450 Bedford Street
Lexington, 02420

iSpecimen Inc. Executives & BODs

iSpecimen Inc. Executives & BODs
# Name Age
1 Ms. Annette Arnold
Vice President of Sales & Business Development
70
2 Ms. Tracy Wilson Curley
Chief Executive Officer, Chief Financial Officer, Treasurer & Director
70
3 Ms. Carly Lejnieks
Vice President of Marketing
70
4 Ms. Brielan Smiechowski
Senior Vice President of Business Development
70
5 Mr. Evan Cox
Senior Vice President of Strategy & Innovation
70
6 Ms. Leslie Hoyt
Senior Vice President of Operations
70

iSpecimen Inc. Competitors